Additional evidence for the therapeutic efficacy of ExSpeU1 is provided by its application in correcting splicing mutations in OTC gene detected in patients with ornithine transcarbamylase deficiency (OTCD; MIM 311250). Here, OTC is linked to ornithine carbamoyltransferase deficiency.